The BioPharm Brief: Reduction, Reach, and Reinforcement

Welcome to the BioPharm Brief, your daily snapshot of the developments shaping the biopharmaceutical industry.

Reduction, reach, and reinforcement mark this week's biologics news, as an RNA interference therapy delivers sharp reductions in a dangerous lipid disorder, a peptide vaccine trial extends its reach into the UK, and a major acquisition reinforces one company's rare disease pipeline.

We'll start with Arrowhead Pharmaceuticals, where phase 3 results for plozasiran, an RNA interference therapy, showed the drug cut triglycerides by up to eighty-one percent in patients with severe hypertriglyceridemia. In the trial's highest-risk patients, those with the most dangerous triglyceride levels and a prior history of pancreatitis, plozasiran reduced pancreatitis events by one hundred percent compared to placebo. The therapy works by suppressing the liver's production of a protein that raises triglyceride levels, and Arrowhead plans to use these results to support a regulatory filing before the end of the year.

Next, Greenwich LifeSciences has expanded its Phase III FLAMINGO-01 trial into the United Kingdom. The trial is evaluating GP2, a peptide vaccine designed to prevent breast cancer recurrence in patients with HER2-expressing tumors. The expansion adds up to ten new UK sites through a collaboration with The Royal Marsden, building on a string of recent regulatory wins that have accelerated enrollment across the trial's global site network.

Finally, Ipsen has completed its acquisition of Memo Therapeutics, adding potravitug, a first-in-class antibody, to its rare disease pipeline. Potravitug targets BK polyomavirus, a common virus that can reactivate in kidney transplant recipients and threaten graft survival. In a Phase 2 trial, patients treated with potravitug were more likely to clear the virus and less likely to develop virus-associated kidney damage, with no approved targeted therapy currently available for this condition.

These three stories capture a full spectrum of biopharma progress, from a therapy delivering dramatic clinical reductions, to a trial reaching more patients, to a company reinforcing its future pipeline.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Takeaways

• Plozasiran cut triglycerides up to 81% and reduced pancreatitis events up to 100% in high-risk patients in Phase 3 trials, positioning Arrowhead for a regulatory filing by year-end.
• Greenwich LifeSciences expanded its FLAMINGO-01 trial of the GP2 breast cancer vaccine into the UK, adding new sites through a partnership with The Royal Marsden.
• Ipsen completed its acquisition of Memo Therapeutics, adding the first-in-class antibody potravitug to its rare disease pipeline for kidney transplant patients facing BK virus reactivation.